Research has found that repurposing FDA-approved drugs can help decrease fibrosis in patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB), also known as butterfly disease. This rare genetic skin disorder causes skin blistering and scarring, leading to fragility. A recent study identified three major drug categories, including antivirals, that can delay fibrosis in RDEB patient tissue samples. The antiviral drug daclatasvir, originally used to treat hepatitis C, showed promising results in reducing fibrosis in mouse models. Researchers are now working to understand how antivirals can decrease fibrosis and plan to start clinical trials with RDEB patients in collaboration with clinicians nationwide.
Source link
Repurposing FDA-approved drugs may decrease fibrosis in butterfly disease
